PAC-5 Gene Expression Signature for Predicting Prognosis of Patients with Pancreatic Adenocarcinoma
| Autor: | Sung-Soo Kim, Miran Jang, Hyeong Rok Yun, Jieun Kim, Ngoc Ngo Yen Nguyen, Yoonhwa Shin, Insug Kang, Joohun Ha, Seok Hoon Ko, Ju Seog Lee, Yong Hwa Jo, Tae Gyu Choi |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2019 |
| Předmět: |
0301 basic medicine
Oncology Cancer Research medicine.medical_specialty endocrine system diseases Pathological staging education lcsh:RC254-282 Article prognostic prediction gene expression signature 03 medical and health sciences 0302 clinical medicine Internal medicine health services administration Gene expression pancreatic adenocarcinoma Medicine Stage (cooking) Gene Pathological business.industry Kinase food and beverages medicine.disease lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens humanities 030104 developmental biology 030220 oncology & carcinogenesis DNA methylation Adenocarcinoma adjuvant therapies business |
| Zdroj: | Cancers Cancers, Vol 11, Iss 11, p 1749 (2019) Volume 11 Issue 11 |
| ISSN: | 2072-6694 |
| Popis: | Pancreatic adenocarcinoma (PAC) is one of the most aggressive malignancies. Intratumoural molecular heterogeneity impedes improvement of the overall survival rate. Current pathological staging system is not sufficient to accurately predict prognostic outcomes. Thus, accurate prognostic model for patient survival and treatment decision is demanded. Using differentially expressed gene analysis between normal pancreas and PAC tissues, the cancer-specific genes were identified. A prognostic gene expression model was computed by LASSO regression analysis. The PAC-5 signature (LAMA3, E2F7, IFI44, SLC12A2, and LRIG1) that had significant prognostic value in the overall dataset was established, independently of the pathological stage. We provided evidence that the PAC-5 signature further refined the selection of the PAC patients who might benefit from postoperative therapies. SLC12A2 and LRIG1 interacted with the proteins that were implicated in resistance of EGFR kinase inhibitor. DNA methylation was significantly involved in the gene regulations of the PAC-5 signature. The PAC-5 signature provides new possibilities for improving the personalised therapeutic strategies. We suggest that the PAC-5 genes might be potential drug targets for PAC. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
| Nepřihlášeným uživatelům se plný text nezobrazuje | K zobrazení výsledku je třeba se přihlásit. |